Earnings Call · Q4 FY2021·2022-02-10

Q4 21EPS -30.25%·Rev n/aQ3 21EPS -31.82%·Rev n/aQ2 21EPS -28.57%·Rev n/aQ1 21EPS -33.33%·Rev n/a⚠ consensus missing

Ultragenyx Pharmaceutical Inc. RARE

Joshua Higa — Senior Vice President, Investor Relations

Emil Kakkis — Chief Executive Officer

Erik Harris — Commercialization Team Leader

Mardi Dier — Chief Financial Officer

Camille Bedrosian — Clinical Development Leader

−0.9%1d on move date−0.8% vs SPY3d−3.5%5d−2.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RARE calls or request research access.

More RARE calls Browse calls Request research access